Hypertensive responses to exercise after 12-weeks of high-intensity interval training or moderate-to-vigorous intensity continuous training in patients with persistent and permanent atrial fibrillation: a non-prespecified post-hoc analysis of a randomized clinical trial.

J Sci Med SportApr 10, 2026 (epub)
Clinical ResearchCardiology

Kimberley L Way, Tori O Roberts, Tasuku Terada et al.

✦ AI-curated · Sources linked

In 30 seconds

This non-prespecified post-hoc analysis of a randomized clinical trial examined exercise blood-pressure responses in adults with persistent or permanent atrial fibrillation assigned to 12 weeks of high-intensity interval training or moderate-to-vigorous continuous training. Blood pressure was measured after a six-minute walk test. A clinically meaningful peak systolic blood-pressure reduction (at least 10 mmHg) occurred in a greater proportion of continuous-training participants than interval-training participants (43% vs 19%, p=0.029). Across the cohort, findings suggested a small reduction in hypertensive response relative to fitness; the authors concluded that either training approach may reduce these responses.

Key findings

  • Clinically meaningful peak systolic blood-pressure reductions occurred in 43% with continuous training versus 19% with interval training (p=0.029).
  • Across the cohort, 55% experienced a reduction in hypertensive response relative to fitness; the reported values were 42 ± 8 mmHg/METs at baseline and 41 + 14 mmHg/METs at follow-up (p=0.0501).
  • Among females, clinically meaningful peak systolic blood-pressure reductions occurred in 43% with continuous training versus 7% with interval training.

Why it matters

Exercise-related blood-pressure responses may be relevant when assessing cardiovascular responses to training in people with atrial fibrillation. These findings suggest that aerobic training could be associated with modest improvement, while the larger proportion with meaningful peak systolic reductions in the continuous-training group may inform further study of training approaches. The results are exploratory rather than definitive.

What to keep in mind

This was a non-prespecified post-hoc analysis, and blood pressure was assessed immediately after a six-minute walk test; the findings do not establish effects on longer-term clinical outcomes.

Source

Published in J Sci Med Sport. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.